PRTC - PureTech forms clinical advisory board for idiopathic pulmonary fibrosis and related lung disorders

PureTech Health (PRTC) announces the formation of its clinical advisory board for idiopathic pulmonary fibrosis ((IPF)) and other progressive fibrosing interstitial lung diseases ((PF-ILDs)).The advisory group will work closely with the company in the advancement of its anti-fibrotic drug LYT-100 (deupirfenidone).LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease, and disorders of lymphatic flow, such as lymphedema."We believe LYT-100 has the potential to treat a wide array of these conditions, including IPF, and the advisory board’s guidance will help us advance LYT-100," CEO Daphne Zohar said.

For further details see:

PureTech forms clinical advisory board for idiopathic pulmonary fibrosis and related lung disorders